Remove Bioinformatics Remove Pharmaceuticals Remove Small Molecule
article thumbnail

Lead Pharma enters into a Research Collaboration and License Agreement with Roche to Develop Oral Small Molecules for Immune Mediated Diseases

The Pharma Data

R&D collaboration building on Lead Pharma’s expertise in the discovery, design and optimization of small molecule treatments. Lead Pharma is a pharmaceutical company focusing on the discovery and development of innovative medicines for the treatment of immune diseases and cancer. About Lead Pharma.

article thumbnail

Unlocking the potential of natural products in drug discovery

Drug Target Review

Between 2000 and 2020, approximately 30 percent of the newly introduced small molecule drugs were derived from natural products. In short, this hypothesis underscores the potential benefits of aligning pharmaceutical development more closely with nature. References Newman DJ, Cragg GM.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AI in Drug Discovery - A Highly Opinionated Literature Review (Part II)

Practical Cheminformatics

While large pharmaceutical companies have data on thousands or even millions of compounds, this data is rarely shared due to intellectual property concerns. Data from 21 million molecules and more than 40,000 assays was securely combined into a multitask model. For classification models, the participants reported a median 2.5-7.5%

Drugs 139
article thumbnail

AI At The Frontier: Empowering Early Career Professionals In Drug Discovery

Elrig

Harini Srinivasan is a Principal Scientific Associate at Serna Bio with over 10 years of research experience in academic institutions, health care organizations and pharmaceutical companies. With a background in Bioinformatics and Computational Biology, she has a keen interest in using technology to solve problems in healthcare and medicine.

article thumbnail

AI-driven drug discovery: insights from Cresset

Drug Target Review

Cresset delivers software solutions and contract research expertise enabling companies around the world to accelerate their small molecule discovery processes efficiently and effectively. Customers include the pharmaceutical, biotechnology and agrochemical industries.

Drugs 64
article thumbnail

Biopharma Executive Perspectives on 2021

The Pharma Data

I actually think neuroscience is going to heat up in 2021,” said Ben Zeskind , co-founder and CEO of Immuneering , which is using bioinformatics and computational biology to develop new drugs in this space, along with oncology and immuno-oncology. In a boone for Slonim’s research focus, the year 2020 has made this molecule a household name.

Vaccine 52
article thumbnail

Using clinical genomics and AI in drug development to elevate success

Drug Target Review

The major hurdles that pharmaceutical companies face are long lead times, high costs and a low probability of success (PoS). Drugs that were developed and commercialised 30+ years ago were relatively simple small molecules. This failure is getting more pronounced by the day.